 |
市場調查報告書
商品編碼
2075110
口溶錠市場：依藥物類別、疾病、年齡層、通路及地區分類Orodispersible Tablets Market, By Drug Class, By Disease Indication, By Age Group, By Distribution Channel, By Geography |
||||||
價格
簡介目錄
預計到 2026 年，口溶錠市場規模將達到 126.2 億美元，到 2033 年將達到 260.4 億美元。預計 2026 年至 2033 年的複合年成長率將達到 10.9%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 126.2億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2026年至2033年 |
| 2026年至2033年預測期間的複合年成長率： | 10.90% | 2033年市場規模預測： | 260.4億美元 |
口溶錠（ODT）是固態單劑量藥物，無需咀嚼或用水送服，即可在口腔內迅速崩壞或溶解。這種劑型的需求日益成長，尤其是在吞嚥傳統片劑困難或不適的兒童和老年患者。
口腔崩解片（ODT）的配方中使用了多種添加劑，例如粘合劑和崩壞。最常用的粘合劑是甲基丙烯酸酯共聚物，它具有很高的內強度，適用於高劑量藥物的配製。此外，它還具有防水性，並且比標準片配方更不易受潮。最常用的崩壞是甘露醇和阿斯巴甜。
市場動態：
全球老年人口的不斷成長預計將推動全球口溶錠市場的成長。老年人由於用藥方便快捷，往往更傾向於自行服藥。此外，老年醫療保健設施的日益完善也促進了市場擴張。
然而，預計未來幾年價格壓力上升將阻礙全球口溶錠市場的成長。
本研究的主要特點：
- 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
- 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
- 本研究根據以下參數介紹了全球口溶錠市場主要參與者的概況：公司概況、產品系列、主要亮點、財務表現和策略。
- 本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品類型升級、市場擴張和行銷策略做出明智的決策。
- 這份「全球口溶錠市場報告」旨在為該行業的各種相關人員提供服務，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
- 相關人員可以利用全球口溶錠市場分析中使用的各種策略矩陣來促進決策。
目錄
第1章：研究目標與前提條件
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章：市場動態、監管與趨勢分析
- 促進因素
- 市場動態
- 慢性病盛行率增加
- 藥物傳輸技術的進步
- 提高病患用藥依從性和便利性
- 人們越來越關注以病人為中心的醫療服務。
- 抑制因子
- 高昂的研發和製造成本
- 藥物相容性的限制和製劑選擇的局限性
- 機會
- 對個人化醫療的需求日益成長
- 數位健康解決方案的廣泛應用
- 開發創新的風味掩蔽技術
- 重點研發速溶製劑。
- 市場動態
- 影響分析
- 主要亮點
- 監管趨勢
- 產品上市及核准
- PEST分析
- 波特五力分析
- 併購情景
第4章：世界各地的口溶錠
- 供給面和需求面分析
- 經濟影響
第5章 全球口溶錠市場：依藥物類別分類，2021-2033年
- 止痛藥
- 止吐藥
- 抗精神病藥物
- 抗發炎藥
- 鎮靜劑和催眠藥
- 抗高血壓藥物
- 其他
第6章 全球口溶錠市場：依疾病分類，2021-2033年
- 疼痛管理
- 過敏和呼吸系統疾病
- 神經病變
- 消化系統疾病
- 心血管疾病
- 其他
第7章 全球口溶錠市場：依年齡層別分類，2021-2033年
- 兒童患者
- 成年患者
- 老年人
第8章 全球口溶錠市場：依通路分類，2021-2033年
- 醫院藥房
- 零售藥房
- 網路藥房
第9章 全球口溶錠市場：依地區分類，2021-2033年
- 北美洲
- 美國
- 加拿大
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
- 中東和非洲
- GCC
- 以色列
- 北非
- 中非
- 其他中東和非洲國家
第10章 競爭格局
- AstraZeneca PLC
- GlaxoSmithKline PLC
- Novartis International AG
- Johnson & Johnson Services, Inc.
- Teva Pharmaceutical Industries Ltd.
- Merck & Co., Inc.
- Pfizer Inc.
- Cipla Limited
- Reddy's Laboratories Ltd.
- Sun Pharmaceutical Industries Ltd.
- Lupin Pharmaceuticals, Inc.
- Torrent Pharmaceuticals Ltd.
- Hoffmann-La Roche Ltd.
- Eisai Co., Ltd.
- Takeda Pharmaceutical Company Limited
第11章
- 調查方法
- 關於本公司
簡介目錄
Product Code: CMI5745
Orodispersible Tablets Market is estimated to be valued at USD 12.62 Bn in 2026 and is expected to reach USD 26.04 Bn by 2033, growing at a compound annual growth rate (CAGR) of 10.9% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 12.62 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 10.90% | 2033 Value Projection: | USD 26.04 Bn |
Orodispersible Tablets (ODTs) are solid unit dosage forms that disintegrate or dissolve rapidly in the mouth without chewing and without the need for water. The demand for this dosage form has been increasing, especially in pediatric and geriatric patient populations who find swallowing conventional tablets difficult or uncomfortable.
ODTs are formulated from various excipients, including binders and disintegrants. The most common binders are methacrylic acid copolymers, which have high internal strength to support the formulation of high dose drugs. They also have the property of water resistance and are less sensitive to moisture than standard tablet formulations. The most popular disintegrants are mannitol and aspartame.
Market Dynamics:
Increasing geriatric population across the globe is anticipated to drive growth of the global orodispersible tablets market. Elderly people prefer self-administration of medications for easy accessibility and convenience. Rising focus on healthcare facilities for the elderly also boosts the market.
However, increased pricing pressure is projected to hinder growth of the global orodispersible tablets market in the coming years.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global orodispersible tablets market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include AstraZeneca PLC, GlaxoSmithKline PLC, Novartis International AG, Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Pfizer Inc., Cipla Limited, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Lupin Pharmaceuticals, Inc., Torrent Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., Eisai Co., Ltd., and Takeda Pharmaceutical Company Limited
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global orodispersible tablets market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global orodispersible tablets market
Detailed Segmentation:
- Global Orodispersible Tablets Market, By Drug Class:
- Analgesics
- Antiemetics
- Antipsychotics
- Anti-inflammatory Drugs
- Sedatives/Hypnotics
- Antihypertensives
- Others
- Global Orodispersible Tablets Market, By Disease Indication:
- Central Nervous System Disorders
- Gastrointestinal Disorders
- Cardiovascular Disorders
- Respiratory Disorders
- Allergy and Asthma
- Others
- Global Orodispersible Tablets Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Orodispersible Tablets Market, By Age Group:
- Pediatric Patients
- Adult Patients
- Geriatric Patients
- Global Orodispersible Tablets Market, By End User:
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Homecare Settings
- Global Orodispersible Tablets Market, By Technology:
- Lyophilization
- Tablet Molding
- Spray Drying
- Sublimation
- Others
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles:
- AstraZeneca PLC
- GlaxoSmithKline PLC
- Novartis International AG
- Johnson & Johnson Services, Inc.
- Teva Pharmaceutical Industries Ltd.
- Merck & Co., Inc.
- Pfizer Inc.
- Cipla Limited
- Dr. Reddy's Laboratories Ltd.
- Sun Pharmaceutical Industries Ltd.
- Lupin Pharmaceuticals, Inc.
- Torrent Pharmaceuticals Ltd.
- F. Hoffmann-La Roche Ltd.
- Eisai Co., Ltd.
- Takeda Pharmaceutical Company Limited
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Orodispersible Tablets, By Drug Class
- Market Orodispersible Tablets, By Disease Indication
- Market Orodispersible Tablets, By Age Group
- Market Orodispersible Tablets, By Distribution Channel
- Market Orodispersible Tablets, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Drivers
- Market Dynamics
- Increasing Prevalence of Chronic Diseases
- Technological Advancements in Drug Delivery
- Enhanced Patient Compliance and Convenience
- Growing Focus on Patient-Centered Care
- Restraints
- High Development and Manufacturing Costs
- Limited Drug Compatibility and Formulation Options
- Opportunities
- Increasing Demand for Personalized Medicine
- Rising Adoption of Digital Health Solutions
- Development of Innovative Taste-Masking Techniques
- Focus on Fast-Dissolving Formulations
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER€(TM)s Analysis
- Merger and Acquisition Scenario
4. Global Orodispersible Tablets
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Orodispersible Tablets Market, By Drug Class, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 €" 2033
- Segment Trends
- Analgesics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Antiemetics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Anti-inflammatory Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Sedatives/Hypnotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Antihypertensives
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
6. Global Orodispersible Tablets Market, By Disease Indication, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€" 2033
- Segment Trends
- Pain Management
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Allergy and Respiratory Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Neurological Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Gastrointestinal Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Cardiovascular Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
7. Global Orodispersible Tablets Market, By Age Group, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2023and 2033 (%)
- Y-o-Y Growth Analysis, 2026€" 2033
- Segment Trends
- Pediatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Adult Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Geriatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
8. Global Orodispersible Tablets Market, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€" 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
9. Global Orodispersible Tablets Market, By Region, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2022€"2033
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
- GCC
- Israel
- North Africa
- Central Africa
- Rest of Middle East & Africa
10. Competitive Landscape
- AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline PLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis International AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Johnson & Johnson Services, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Cipla Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Reddy's Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Lupin Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Torrent Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Eisai Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
11. Section
- Research Methodology
- About us
